(1) Whether (a) there are dates by which pharmaceutical companies must submit their application each year in order to establish the Single Exit Price (SEP) and (b) his department must approve or reject the submission; if not, why not in each case; if so, what are the relevant details in each case; (2) when the new SEP comes into force; (3) whether his department met the due date in (a) 2008 and (b) 2009 for approving all new SEP; if not, (i) why not, (ii) how many were (aa) approved and (bb) not approved by the deadline for each year and (iii) on which date was the new SEP approved for all medicines that failed to meet the deadline; (4) how many people work in the Pharmaceutical Economic Unit that approves the SEP?